IN2 ASSESSEMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTIC OBSERVATIONAL STUDY IN FRANCE
Abstract
Authors
S Payet L Riou França K Le Lay JF Dhainaut B Vallet R Launois